Connect with us

Business

Ontario securities regulator hits cannabis producer Cronos for faulty financial statements

Published

on

Ontario’s securities regulator said it entered into settlement agreements with cannabis producer Cronos Group and one of its former top executives over allegations involving a breach of securities law and conduct contrary to the public interest.

The Capital Markets Tribunal will hold a hearing Oct. 24 to weigh approval of the settlement agreements. The details of those agreements are not public.

Cronos is accused of failing to file interim financial statements prepared in accordance with applicable generally accepted accounting principles (GAAP) and acting in a manner contrary to the public interest.

The Ontario Securities Commission (OSC) alleges William Hilson, who was Cronos’ chief financial officer and later chief commercial officer, acted in a manner contrary to the public interest.

“When public cannabis companies issue financial statements that do not provide accurate information about their financial performance and condition and fail to have adequate controls, they undermine confidence in Ontario’s capital markets and leadership in the cannabis space,” the OSC said in its statement of allegations.

A spokesperson for Cronos said the company is unable to comment as settlement details remain subject to confidentiality.

Hilson did not immediately respond to MJBizDaily queries for comment.

The OSC said Cronos is being held accountable for improperly recognizing 7.6 million Canadian dollars ($5.6 million) in revenue in 2019 “and for subsequently overstating virtually all of its U.S. goodwill and a significant portion of its U.S. intangible assets by a collective amount of $234.9 million (322.8 Canadian dollars) in its Q2 2021 interim financial statements.”

In February 2020, Toronto-headquartered Cronos announced a delay to its 2019 annual financial statements.

The following month, Cronos said the company’s audit committee was examining “the appropriateness” of the recognition of revenue from several bulk resin purchases and sales of products through the wholesale channel.

Weeks later, Cronos said unaudited interim financial statements for the first, second and third quarters of 2019 would be restated and revenue would be reduced for the quarters ended March 31, 2019, and Sept. 30, 2019.

In February 2022, Cronos filed more restated interim financial statements, this time for the quarter and half-year period ended June 30, 2021.

Cronos concluded that it should have recorded an impairment charge of $234.9 million on goodwill and intangible assets related to its U.S. reporting unit.

The first revenue recognition error in 2019 involved the exchange of cannabis dry flower for cannabis resin with a third party in the first quarter, according to the OSC.

This deal resulted in overstated revenue of approximately CA$2.5 million, the OCS said, adding that the transaction “lacked commercial substance” and the revenue should not have been recognized.

The transaction did not meet the criteria for revenue recognition in accordance with GAAP, according to the regulator.

Three similar transactions occurred in the quarter ended Sept. 30, 2019, with the same third party, all of which “did not meet the criteria for revenue recognition,” the OSC said.

The securities regulator did not name the third party.

The OSC said the errors resulted in Cronos overstating revenue by approximately CA$2.1 million for the three and nine months ended Sept. 30, 2019.

The OSC alleges that Hilson “played a significant role in a further wholesale transaction in which Cronos improperly recognized CA$3 million in revenue.”

Hilson served as CFO at Cronos from September 2016 until April 2019 and CCO from April 2019 to December 2019.

The OSC said Hilson signed off on the interim financial statements for the three months ending Sept. 30, 2019.

However, the wholesale “transaction did not, in fact, meet the criteria for revenue recognition in accordance with applicable generally accepted accounting principles.”

“Hilson failed to take appropriate steps to address the handling of revenue recognition issues” for the transaction, “including by not ensuring that an analysis of revenue recognition in respect of the transaction had been prepared and considered by the company prior to its completion of Q3 2019 Interim Financial Statements.”

Source: https://mjbizdaily.com/ontario-securities-commission-hits-cannabis-producer-cronos-for-faulty-financial-statements/

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News